AGIO — AGIOS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1439222 ·
Last close
$28.33
Market Cap
$1.68B
52W High
$36.35
52W Low
$24.29
ADV30
1,125,894
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,746,000 | 19,427,000 | -110,025,000 | -99,111,000 | 1,184,990,000 | 113,600,000 | 75,875,000 |
| Dec 2025 | 19,967,000 | 18,088,000 | -121,578,000 | -108,039,000 | 1,297,225,000 | 89,130,000 | 104,111,000 |
| Sep 2025 | 12,880,000 | 11,201,000 | -116,869,000 | -103,433,000 | 1,385,705,000 | 92,710,000 | 101,375,000 |
| Jun 2025 | 12,455,000 | 10,753,000 | -127,056,000 | -112,020,000 | 1,471,237,000 | 80,871,000 | 101,682,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-380,408,000
Investing CF
$405,909,000
Financing CF
$9,135,000
CapEx
$-14,319,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$11.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-802,486,000
Inventory
$35,087,000
Receivables
$10,577,000
ST Investments
$765,295,000
EBIT TTM
$-475,528,000
Pretax Income TTM
$-423,619,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,048,000
EBITDA
$-470,265,984
Free Cash Flow
$-267,222,000
Enterprise Value
$972,238,080
Total Cash
$737,038,016
Total Debt
$35,745,000
Shares Out
59,471,609
Trailing EPS
$-7.26
Book Value
$18.69
ROE
-32.8%
ROA
-21.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 54,028,000 | -472,132,000 | -412,781,000 | 1,297,225,000 | 104,111,000 | — | -372,977,000 |
| Dec 2024 | 36,498,000 | -425,737,000 | 673,725,000 | 1,663,199,000 | 122,243,000 | — | -389,841,000 |
| Dec 2023 | 26,823,000 | -391,487,000 | -352,088,000 | 937,118,000 | 126,099,000 | — | -296,062,000 |
| Dec 2022 | 14,240,000 | -389,047,000 | -231,801,000 | 1,238,718,000 | 137,904,000 | — | -309,478,000 |
TTM Snapshot
Revenues TTM
$19,879,000
NetIncome TTM
$686,078,000
OpCashFlow TTM
$0
Assets (Latest)
$1,663,199,000
Forward EPS
$-4.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.69B | $117.59 | — |
| ANAB | ANAPTYSBIO, INC | $1.68B | $57.77 | — |
| INVA | Innoviva, Inc. | $1.67B | $22.68 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $1.70B | $29.36 | — |
| GENB | Generate Biomedicines, Inc. | $1.71B | $13.34 | — |
News headlines (Yahoo Finance, 1h cache)
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
2026-05-25 15:08 · Yahoo
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
2026-05-22 14:18 · Yahoo
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
2026-05-22 13:15 · Yahoo
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
2026-05-19 17:03 · Yahoo
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility
2026-05-15 06:13 · Yahoo
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story
2026-05-15 05:11 · Yahoo
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation
2026-05-13 19:19 · Yahoo
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
2026-05-13 15:21 · Yahoo
Sector Update: Healthcare Stocks Gain in Afternoon Trading
2026-05-12 17:54 · Yahoo
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
2026-05-12 13:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.